RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
July 10, 2025
RegMed Investors (RMi) Closing Bell: Some cooling yet, sector stays within an upside course
June 30, 2025
RegMed Investors (RMi) Closing Bell: the sword hung by a single horsehair, implying an ever-present peril facing share pricing
June 27, 2025
RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower
June 26, 2025
RegMed Investors (RMi) Closing Bell: Econs cried havoc and let slip the algo dogs of electronic trading
June 25, 2025
RegMed Investors (RMi) Closing Bell: Electronic trading slipped in to minimize earlier share pricing blast circumference
June 24, 2025
RegMed Investors (RMi) Closing Bell: clicking on the after burners
June 24, 2025
RegMed Investors’ (RMi) pre-open: get it up
June 23, 2025
RegMed Investors (RMi) Closing Bell: Sector has minor collateral damage
June 20, 2025
RegMed Investors (RMi) Closing Bell: Luckily, the canopy opened
June 20, 2025
RegMed Investors’ (RMi) pre-open: walking back the cat
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors